middle.news

Clarity Pharmaceuticals Unveils Superior Prostate Cancer Imaging and Therapy Data

9:57am on Thursday 6th of August, 2026 AEST Healthcare
Read Story

Clarity Pharmaceuticals Unveils Superior Prostate Cancer Imaging and Therapy Data

9:57am on Thursday 6th of August, 2026 AEST
Key Points
  • 64Cu-SAR-bisPSMA detects more lesions than FDA-approved PSMA PET agents
  • Next-day imaging boosts lesion visibility and diagnostic confidence
  • 67Cu-SAR-bisPSMA shows promising safety and efficacy in advanced prostate cancer
  • Multiple Phase III trials underway to support regulatory approvals
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE